GlassScriptPhysician profile
James R Sarrett
NPI 1669467056
$5,041.61
in general payments reported to CMS, 2019-2025
38 companies · $74.63 in 2025
The $74.63 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $433 · 2021: $1,002 · 2022: $1,021 · 2023: $1,162 · 2024: $539 · 2025: $74.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $792.34 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Abbott Laboratories | $440.90 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $439.29 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $352.55 | 2019-2024 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $346.36 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Sanofi-Aventis U.S. LLC | $280.87 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $239.26 | 2021-2022 | |
| Glaxosmithkline, LLC. | $193.06 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $177.46 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $170.16 | 2020-2023 | Belsomra, Steglujan, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $149.32 | 2020-2023 | Trintellix |
| Genentech USA, INC. | $145.42 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $141.36 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.76 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $133.37 | 2023-2024 | Rexulti |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sarrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.